Advances of toripalimab for the treatment of melanoma
10.3969/j.issn.1000-8179.2019.16.724
- VernacularTitle:特瑞普利单抗治疗黑色素瘤的适应证分析*
- Author:
Bixia TANG
1
;
Lu SI
;
Jun GUO
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所肾癌黑色素瘤内科
- Keywords:
toripalimab;
anti PD-1 antibody;
melanoma
- From:
Chinese Journal of Clinical Oncology
2019;46(16):857-860
- CountryChina
- Language:Chinese
-
Abstract:
On December 27, 2018, the first domestic anti-PD-1 antibody, toripalimab, was approved by the State Food and Drug Ad-ministration for the treatment of advanced melanoma after the failure of standard treatment. This represented a major breakthrough in the field of biopharmaceuticals in China and laid the foundations for pharmaceutical research and development in the field of tu-mor immunotherapy. In this article, we summarize the clinical research of the treatment of melanoma, the application of toripalimab in this field, and the global development of other anti-PD-1 antibodies, to provide guidance for the research and treatment of melano-ma in China.
